Shanghai Sigma-Audley New Material Technology (revision 33)
Old revision·19:29, 19 Apr 2025·BiliaryBea
| Shanghai Sigma-Audley New Material Technology Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Shanghai Sigma-Audley New Material Technology Co., Ltd. |
| Trading name | SSA |
| Other designations | SSA Biotech, Shanghai Sigma-Audley New Material Technology |
| Identity | |
| Founded | 2018 |
| Headquarters | Shanghai, China |
| Industry | Research-compound supply |
| Shop domain | Visit SSA |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| Organisation infobox · conventions | |
Shanghai Sigma-Audley New Material Technology Co., Ltd. (trading as SSA; shanghaisigmaaudley.com) is a research-compound supplier trading as SSA from Shanghai, China, incorporated in 2018 under a registered name in the new-materials sector, and distributing research peptides and related materials with batch documentation.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]The registered legal name describes the organisation as a new-material technology company rather than a pharmaceutical or biochemical one.[1] That is a common pattern among entities in this sector and is not in itself remarkable, but it is worth stating in an encyclopedia article because the registered business scope is the only formal statement of what an organisation is licensed to do, and it does not always match what it sells.
The trading name contains "Sigma", which is also the name of a large and entirely separate international reference-standards supplier. As with several organisations covered here, no source available to this wiki establishes any relationship between them, and the shared word should not be read as implying one.[2]
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Reports reaching this wiki describe vialled lyophilised material with a batch-specific certificate, packaged with a cold pack for the incretin analogues.[5] Packaging descriptions have been consistent enough across submissions to suggest a settled fulfilment process, which is a modest but real observation about an organisation of this type.
The organisation's own material describes a product range and documentation practice; it makes no certification claim that this wiki has been able to corroborate, and any such claim would in any case require assessment against the applicable framework rather than acceptance at face value.[6][2]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide, retatrutide | Batch certificate, HPLC trace |
| Research peptides | Repair and secretagogue peptides | Batch certificate |
| SARMs | Bulk and capsuled | Certificate, variable detail |
| Injectable oils and raw materials | Bulk | Certificate, limited detail |
Documentation detail reported by purchasers is markedly better for the incretin analogues than for the bulk categories, a gradient visible across most organisations covered on this wiki and probably reflecting where purchaser scrutiny is concentrated.[5]
Independent testing record
[edit]Submitted reports on SSA material to July 2026 are concentrated on tirzepatide and semaglutide, with a smaller set on repair peptides. Reported area percent figures have clustered in the high nineties, and where a certificate accompanied the sample the two figures have generally been close.[5]
See also
References
- ^ a b National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ World Health Organization, Good Manufacturing Practices for Pharmaceutical Products: Main Principles, WHO Technical Report Series. The general framework against which a GMP claim is assessed.